Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria.
The DOI matches its Crossref record.
Abstract
The therapeutic efficacy and toxicity of artesunate (2mg/kg/day for five days, then 1 mg/kg/day for two days: total=12 mg/kg) was compared with that of artemether (4 mg/kg followed by 2 mg/kg/day for two days, then 1 mg/kg/day for four days: total=12 mg/kg) for the treatment of recrudescent multidrug-resistant falciparum malaria in an open randomized trial in 443 patients living on the western border of Thailand. Parasite and fever clearance times were similar in both groups; within 48 hr 94% (95% confidence interval [CI]=91-96%]) of the treated patients were aparasitemic and 93% (95% CI=89-96%) were afebrile. Symptom resolution and resolution of hepatomegaly were slightly slower in the artesunate group; adjusted hazards ratio=1.5 (95% CI=1-2.0, P < 0.01) and 2.2 (95% CI=1.4-8, P=0.04), respectively. There was no significant difference in times to resolution or development of anemia or splenomegaly between treatment groups. By day 28, 3% (95% CI=0.3-5%) of the patients treated with artesunate and 6% of those treated with artemether (95% CI = 2-9%) had recurrent infections (P=0.3). Both regimens were very well tolerated, with no significant adverse effects attributable to either derivative. Overall, these data suggest that the two oral artemisinin derivatives are safe, highly effective, and result in equivalent therapeutic responses in the treatment of drug-resistant falciparum malaria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Artemisinin-Based Combination Treatment of Falciparum Malaria
Nosten, F., & White, N. J. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.181 · Cited by 673
Self-citationFerreira, J. F. S., Luthria, D. L., Sasaki, T., & Heyerick, A. (2010) · Molecules · doi:10.3390/molecules15053135 · Cited by 531
Factors contributing to anemia after uncomplicated falciparum malaria.
Price, R. N., Simpson, J. A., Nosten, F., Luxemburger, C., Hkirjaroen, L., ter Kuile, F., Chongsuphajaisiddhi, T., & White, N. J. (2001) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.2001.65.614 · Cited by 404
Self-citationAdverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.
Price, R., van Vugt, M., Phaipun, L., Luxemburger, C., Simpson, J., McGready, R., ter Kuile, F., Kham, A., Chongsuphajaisiddhi, T., White, N. J., et al. (1999) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.1999.60.547 · Cited by 262
Self-citationArtesunate Induces ROS-Mediated Apoptosis in Doxorubicin-Resistant T Leukemia Cells
Efferth, T., Giaisi, M., Merling, A., Krammer, P. H., & Li-Weber, M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000693 · Cited by 256
Efferth, T., Marschall, M., Wang, X., Huong, S.-M., Hauber, I., Olbrich, A., Kronschnabl, M., Stamminger, T., & Huang, E.-S. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0300-8 · Cited by 182
“Propitious features of ART are the activity against multidrug-resistant Plasmodium strains [ 14 ], its good tolerability, and its lack of significant adverse side effects [15, 16].”
BackgroundDouglas, N. M., Nosten, F., Ashley, E. A., Phaiphun, L., van Vugt, M., Singhasivanon, P., White, N. J., & Price, R. N. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq249 · Cited by 145
Self-citationMcGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050253 · Cited by 136
“]. Artemisinin and its derivatives temporarily suppress erythropoeisis, but this “trades off” against the benefit of rapidly reducing parasitaemia and thereby reducing malaria-associated haemolysis. The slightly lower levels of haematocrit and haemoglobin at day 7 in the AS7 group were expected because of the longer h…”
BackgroundSelf-citationGuesmi, F., Bellamine, H., & Landoulsi, A. (2018) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2018-0107 · Cited by 27
“…activating MAP kinases (Reuter et al., 2010) and nuclear transcription factors (NF-κB, AP-1, and p53) that possibly lead to upregulation of death proteins or production of inhibitors of survival proteins leading to apoptosis and cell death (Price et al., 1998; Lowe et al., 1993; Tu et al., 2016).”
Background
Metadata
- Authors
- Price, R., van Vugt, M., Nosten, F., Luxemburger, C., Brockman, A., Phaipun, L., Chongsuphajaisiddhi, T., & White, N.
- Venue
- The American journal of tropical medicine and hygiene
- Published
- 1998-12
- Volume
- 59
- Issue
- 6
- Pages
- 883-888
- ISSN
- 0002-9637 (ISSN-L)
- OpenAlex
- W1937991665
- Cited by
- 74
- References
- 0
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.